Jiangzhuo Prescription ,Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF) (JZF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01265160 |
Recruitment Status
: Unknown
Verified September 2010 by Guang'anmen Hospital of China Academy of Chinese Medical Sciences.
Recruitment status was: Recruiting
First Posted
: December 23, 2010
Last Update Posted
: December 23, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Metabolic Syndromes Hyperlipidemia |
Study Type : | Observational |
Estimated Enrollment : | 240 participants |
Observational Model: | Case Control |
Time Perspective: | Prospective |
Official Title: | Jiangzhuo Prescription ,Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF) |
Study Start Date : | November 2010 |
Estimated Primary Completion Date : | May 2011 |
Estimated Study Completion Date : | June 2011 |

Group/Cohort |
---|
the group of Jiangzhuo prescription |
the group of fenofibrate |
the group of placebo |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- 1. Consistent with diagnosed hyperlipidemia, TG≥2.26mmol/L and ≤7.0mmol/L. 2. Aged 18-65 years old. 3.BMI ≥ 24kg/m2, but <35 kg/m2. 4. Waist circumference ≥ 90cm (male) or waist circumference ≥ 80cm (women). 5. Comply with any of the following 3 :bloode pressure elevated levels of:SBP ≥130mmHg or DBP ≥85mmHg; fasting plasma glucose (FPG) increased: FPG ≥ 100mg/dl (5.6mmol / l ), or previously diagnosed type 2 diabetes or have received appropriate treatment.
Exclusion Criteria:
-
1. Has been used to control lipidsdrugs, but use the time for those below the 3 month.
2.Secondary dyslipidemia, such as nephrotic syndrome, hyperthyroidism, etc. 3.Taking thyroid medications and other drugs that affect lipid metabolism, such as high-dose thiazide diuretics, β-receptor blockers, corticosteroids.
4.Severe diseases of heart, lung, liver, kidney, brain, blood ,etc. 5.With the treatment of insulin, sulfonylureas, rosiglitazone or metformin. 6.3 months prior to the study of myocardial infarction or unstable angina confirmed.
7.Uncontrolled blood sugar or after controlling FPG>7.0mmol/L or 2hPG>11.1mmol/L 8.Uncontrolled blood pressure or after contraolling blood pressure>140/90mmHg 9.ALT≥80mmol/L 10.Pregnancy, for pregnancy or breast-feeding women 11.Allergis of fibrates or Chinese medicine 12.Mental illness 13.Cancer patients 14.History of gallbladder disease or cholelithiasis 15.With the treatment of Cyclosporine or coumarin anticoagulants 16.The patient with other clinical studies in the past 3 months 17.History of alcoholism and drug dependence

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01265160
Contact: Fengmei Lian, PHD | 0086-010-88001402 | lfm565@sohu.com |
China | |
Beijing Chinese Medicine Hospital | Recruiting |
Beijing, China | |
Contact: Bai Chang, PHD 13611089962 | |
Beijing Ji Shui Tan Hospital | Recruiting |
Beijing, China | |
Contact: Xia Wang 13681007636 | |
Beijing Medical University,DONGZHIMEN Hospital | Recruiting |
Beijing, China | |
Contact: Hongfang Liu, PHD 0086-010-84013243 lhfdoctor@sohu.com | |
Civil Aviation General Hospital | Recruiting |
Beijing, China | |
Contact: Yu Zhao, PHD 13522424090 |
Responsible Party: | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
ClinicalTrials.gov Identifier: | NCT01265160 History of Changes |
Other Study ID Numbers: |
81929 |
First Posted: | December 23, 2010 Key Record Dates |
Last Update Posted: | December 23, 2010 |
Last Verified: | September 2010 |
Additional relevant MeSH terms:
Syndrome Metabolic Syndrome X Hyperlipidemias Hyperlipoproteinemias Disease Pathologic Processes Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders |
Metabolic Diseases Dyslipidemias Lipid Metabolism Disorders Fenofibrate Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents |